Das in Pennsylvania ansässige Unternehmen JBS Science gab heute bekannt, dass es vom National Cancer Institute den mit 3 Millionen US-Dollar dotierten Bridge Award for Small Business Innovation Research IIB erhalten hat. Das Unternehmen entwickelte das erste Flüssigbiopsieprodukt, bei dem es sich um ein Urin-DNA-Screening auf Leberzellkrebs im Frühstadium (HCC) handelt.
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of Leberkrebs. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating Tumor DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS sagte, es habe mit James Hamilton vom Johns Hopkins University Medical Center und Hie-Won Hann vom Thomas University Hospital zusammengearbeitet, um die Entwicklung eines Leberkrebs-Urintests voranzutreiben.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
